These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 23573648)

  • 1. Choosing a drug-eluting stent: how are CYPHER and TAXUS different?
    Perin EC
    J Invasive Cardiol; 2004 Sep; 16 Suppl F():12F-16F; discussion 18F-21F. PubMed ID: 23573648
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-eluting stents.
    Whitlow P
    J Invasive Cardiol; 2004 Jul; 16(7 Suppl):2S-6S. PubMed ID: 23573564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravascular ultrasound assessment of expansion of the sirolimus-eluting (cypher select) and paclitaxel-eluting (Taxus Express-2) stent in patients with diabetes mellitus.
    Jensen LO; Maeng M; Mintz GS; Christiansen EH; Hansen KN; Galloe A; Kelbaek H; Hansen HS; Joergensen E; Lassen JF; Thuesen L; Thayssen P
    Am J Cardiol; 2008 Jul; 102(1):19-26. PubMed ID: 18572030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [PTCA with drug eluting stent. 90% fewer restenoses in high risk patients].
    MMW Fortschr Med; 2004 Aug; 146(33-34):53. PubMed ID: 15526636
    [No Abstract]   [Full Text] [Related]  

  • 5. [Drug-eluting stents for diabetic patients. A critical appraisal of the currently available data from randomized trials].
    Silber S; Herdeg C
    Herz; 2008 Apr; 33(3):196-205. PubMed ID: 18568314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Safety and current indications during "real life" use of sirolimus-eluting coronary stents in Germany. Results from the prospective multicenter German Cypher Registry].
    Zahn R; Hamm CW; Zeymer U; Schneider S; Nienaber CA; Richardt G; Kelm M; Levenson B; Bonzel T; Tebbe U; Schöbel WA; Sabin G; Senges J;
    Herz; 2004 Mar; 29(2):181-6. PubMed ID: 15057439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which parameter should be chosen as primary endpoint for randomized drug-eluting stent studies?
    Silber S
    J Interv Cardiol; 2004 Dec; 17(6):375-85. PubMed ID: 15546289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Procedural success and 10-month outcome between Cypher and TAXUS drug-eluting stents for the treatment of in-stent restenosis].
    Chen JL; Yang YJ; Qiao SB; Yao M; Qin XW; Xu B; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Li JJ; Gao RL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Apr; 35(4):305-7. PubMed ID: 17711652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial.
    Kim WJ; Lee SW; Park SW; Kim YH; Yun SC; Lee JY; Park DW; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Lee BK; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Park WJ; Kim HS; Chae JK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Choi YJ; Cheong SS; Yang TH; Jang JS; Her SH; Park SJ;
    Circulation; 2011 Aug; 124(8):886-92. PubMed ID: 21810659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
    Jiménez-Quevedo P; Sabaté M; Angiolillo DJ; Alfonso F; Hernández-Antolín R; SanMartín M; Gómez-Hospital JA; Bañuelos C; Escaned J; Moreno R; Fernández C; Fernández-Avilés F; Macaya C;
    Eur Heart J; 2007 Aug; 28(16):1946-52. PubMed ID: 17562666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial.
    Pache J; Dibra A; Mehilli J; Dirschinger J; Schömig A; Kastrati A
    Eur Heart J; 2005 Jul; 26(13):1262-8. PubMed ID: 15737962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents.
    Kitoga M; Pasquet A; Preumont V; Kefer J; Hermans MP; Vanoverschelde JL; Buysschaert M
    Diabetes Metab; 2008 Feb; 34(1):62-7. PubMed ID: 18069029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards defining the role of drug eluting stents.
    Tarantini G; Ramondo A; Razzolini R
    Minerva Cardioangiol; 2008 Feb; 56(1):29-34. PubMed ID: 18432166
    [No Abstract]   [Full Text] [Related]  

  • 16. [Drug-eluting stents and other anti-restenosis devices].
    Moreno R
    Rev Esp Cardiol; 2005 Jul; 58(7):842-62. PubMed ID: 16022816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?
    Buellesfeld L; Grube E
    Herz; 2004 Mar; 29(2):167-70. PubMed ID: 15054589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).
    Kereiakes DJ; Cutlip DE; Applegate RJ; Wang J; Yaqub M; Sood P; Su X; Su G; Farhat N; Rizvi A; Simonton CA; Sudhir K; Stone GW
    J Am Coll Cardiol; 2010 Dec; 56(25):2084-9. PubMed ID: 21144968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Could Paclitaxel-eluting stents be superior to sirolimus-eluting stents for the treatment of saphenous vein graft lesions?
    Brilakis ES; Banerjee S
    Am J Cardiol; 2010 Nov; 106(9):1367-8. PubMed ID: 21029842
    [No Abstract]   [Full Text] [Related]  

  • 20. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
    Dibra A; Kastrati A; Mehilli J; Pache J; Schühlen H; von Beckerath N; Ulm K; Wessely R; Dirschinger J; Schömig A;
    N Engl J Med; 2005 Aug; 353(7):663-70. PubMed ID: 16105990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.